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Background/aim: The aim of this study was to evaluate perfusion computed tomography (PCT) findings in patients with Alzheimer
disease and to compare them with those of patients without dementia.
Materials and methods: PCT was performed in 35 patients: 20 with Alzheimer disease (mean age, 69.7 ± 5.5 years) and 15 control
subjects (mean age, 67.5 ± 3.5 years). Control subjects were elderly individuals with no cognitive problems who were admitted with
headaches. All PCT examinations were performed on a 4-slice CT unit. The PCT analysis software program was used to calculate
regional cerebral blood flow (rCBF), regional cerebral blood volume (rCBV), regional time-to-peak (rTTP) values in the bilateral
frontal, temporal, and occipital cortices, and bilateral lentiform nucleus.
Results: rCBF values in the bilateral frontal and temporal cortices and bilateral lentiform nucleus were significantly lower in the patients
with Alzheimer disease than in the control subjects. There were no significant differences in rCBV values between Alzheimer disease
and the control group. rTTP values in all cortical areas and bilateral lentiform nucleus were significantly higher in the patients with
Alzheimer disease than in the control subjects.
Conclusion: PCT is a rapid and reliable imaging modality for evaluating brain perfusion in Alzheimer disease.
Key words: Alzheimer disease, brain perfusion, perfusion computed tomography

1. Introduction
Alzheimer disease (AD) occurs in more than half of
patients with dementia and is a progressive, degenerative
neurological disorder (1). The aging population is
increasing and AD is becoming an increasingly important
public health problem. Diagnosis of AD is made via a
combination of clinical history, the results of physical
and neurological examinations, and neuroimaging and
laboratory evaluations (2). Neuropathological studies
suggest that evidence of AD may be present in the brain
years before the onset of clinical symptoms. Identification
of AD at the earliest possible time is crucial for optimal
care and treatment. Therefore, recent studies have focused
on prodromal AD (3).
Neuroimaging studies are used in the diagnosis
of dementia. Structural techniques such as computed
tomography (CT) and magnetic resonance imaging (MRI)
allow for evaluation of the degree of cerebral atrophy and
detection of organic causes of dementia. Newer imaging
techniques such as single photon-emission CT (SPECT),
* Correspondence: bkarakurum@hotmail.com
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positron emission tomography (PET), and perfusion MRI
are useful to evaluate blood perfusion in AD dementia and
other dementia groups (4–6). Although these techniques
have been shown to be valuable, they are often not readily
available. Perfusion CT (PCT) is another perfusion
technique that provides rapid and minimally invasive
assessment of brain perfusion. There are a few studies
concerning PCT in which dementia has been reported
(6–8). The goal of the present study was to evaluate the
usefulness of PCT in assessing brain perfusion in patients
with AD and to compare it with that of patients without
dementia.
2. Materials and methods
This study was approved by the Institutional Review Board
of our university hospital and written informed consent
was obtained from all subjects. Twenty patients with AD
were recruited among outpatients visiting the Neurology
Department of our university. Clinical diagnosis of
dementia was made according to criteria in the DSM-
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IV and probable AD was determined by excluding other
dementias in accordance with criteria from the National
Institute of Neurological and Communicative Disorders
and Stroke and the AD and Related Disorders Association
(NINCDS-ADRDA). Patients showed mini-mental state
examination (MMSE) scores ranging from 14 to 26. The
MMSE is a standardized, 30-point scale that encompasses
the following items: orientation to time (5 points),
orientation to place (5 points), word registration (3 points),
attention (5 points), word recall (3 points), naming (2
points), repetition (1 point), following commands (3
points), reading (1 point), writing (1 point), and pentagon
copying (1 point).
The 15 control subjects were healthy individuals with
no cognitive problems who visited our outpatient clinic
complaining of headaches and who showed normal
results on cranial CT. All PCT examinations were done on
the same 4-detector CT scanner (Sensation 4; Siemens).
Routine whole-brain CT scans were done before and after
PCT. A volume of 40 mL of iodinated contrast medium
(370 mg iodine/mL) was injected via a 14-gauge cannula
into the antecubital fossa with an automatic injector. The
injection rate was 4 mL/s and the delay time was 5 s. Forty
images were obtained from the level of the basal ganglia.
Slice thickness was 10 mm. All perfusion images were
postprocessed with PCT analysis software on a workstation
(Wizard; Siemens). We used the standard convolution
method for CT perfusion processing. Maximum intensity
projection perfusion, cerebral blood flow (CBF), cerebral
blood volume (CBV), and time to peak (TTP) maps
were created. The region of interest (ROI) was placed
superior to the sagittal sinus for the assessment of
perfusion parameters. Relative CBF (rCBF), relative CBV
(rCBV), and relative TTP (rTTP) values were measured
symmetrically on maps. All symmetric ROIs were drawn
by hand on the maximum intensity projection perfusion
image by a single radiologist (T.Y.) in the bilateral frontal,
temporal, and occipital cortices, and bilateral lentiform
nucleus (Figures 1a, 1b, 1c, and 1d).
We investigated differences in sociodemographic
features between the groups with the chi-square test for
categorical variables. Quantitative data obtained from the
frontal, temporal, and occipital cortices and the lentiform
nucleus were compared by independent t-test. P < 0.05 was
considered significant.
3. Results
Demographic features of the AD patients and control
subjects are listed in Table 1. There were no significant
differences between the two groups. Values for rCBF
are listed in Table 2. Values for the bilateral frontal and
temporal cortices and bilateral lentiform nucleus were

significantly lower in the AD group than in the control
group.
Values for rCBV are listed in Table 3. Values for the
bilateral temporal cortex were lower in the AD group
than in the control group, but these differences were
not significant. Values obtained from bilateral frontal
and occipital cortices and lentiform nucleus were not
significantly different between the AD patients and the
control group.
Values for rTTP are listed in Table 4. Values for the
bilateral frontal, temporal, and occipital lobes, and the
bilateral lentiform nucleus were significantly higher in the
AD group than they were in the control group.
4. Discussion
CT is the most widely used and oldest imaging modality
used to evaluate dementia patients. This technique has
been used to determine reversible causes of dementia
such as normal pressure hydrocephaly, chronic subdural
hematoma, mass lesion (i.e. large meningioma), and
infection. MRI is preferred to identify specific pathologies
such as atrophy of the medial temporal lobe, hippocampal
formation, or parahippocampal gyrus, each of which is
highly predictive of AD (5).
Magnetic resonance spectroscopy is useful in the
differential diagnosis and evaluation of progression of
dementia. Findings of increased myo-inositol to creatine
levels, increased choline to creatine levels, and decreased
N-acetylaspartate to creatine levels in the medial temporal
lobe, and to a lesser degree in the parietal lobe, are markers
of early stage AD (9).
Volumetric studies evaluate volume loss in limbic
structures such as the entorhinal cortex, hippocampus,
amygdala, and hypothalamus. Magnetic resonance
volumetric analysis may help in distinguishing patients
with mild cognitive impairments (at risk for proceeding to
AD) from normal elderly subjects (10).
Several studies showed cerebral perfusion in AD,
other dementia groups, and mild cognitive impairment
patients. Caroli et al (3) showed that parahippocampal
and inferior temporal hypoperfusion in amnestic mild
cognitive impairment patients correlated with conversion
to AD. Some studies have also shown that decreased blood
flow in the temporoparietal association area is common
in early stage AD, before cerebral atrophy is detectable. As
dementia progresses, blood flow decreases in the frontal
lobe and is relatively well preserved in the pons, primary
motor cortex, and primary visual cortex of the occipital
lobe, basal ganglia, and thalamus (7,8,11–20).
Perfusion MR using dynamic susceptibility contrastenhanced MRI can show decreased rCBV in the temporal
and parietal regions. This finding correlates with the
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Figure 1. MIP perfusion of pCT at the basal ganglia. A-Frontal, B-Temporal, C-Occipital, D-Lentiform nucleus with freehand drawn
ROI.
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Table 1. Demographic features of the subjects included in the study.
Number

Sex

Age (years)

Alzheimer disease

20

12 F, 8 M

69.7 ± 5.5

Control subjects

15

11 F, 4 M

67.5 ± 3.5

0.350

0.091

P-value
M: male, F: female.

Table 2. Regional cerebral blood flow values determined by perfusion computed tomography in patients
with Alzheimer disease and control subjects.
Brain region

Alzheimer disease

Control subjects

P-value

Right frontal cortex

22.3 ± 3.6

27.5 ± 5.7

0.002

Left frontal cortex

21.6 ± 4.1

28.5 ± 6.6

0.001

Right temporal cortex

26.1 ± 4.4

32.0 ± 6.5

0.002

Left temporal cortex

25.7 ± 4.9

32.5 ± 6.1

0.001

Right occipital cortex

26.6 ± 6.5

32.2 ± 8.7

0.956

Left occipital cortex

26.3 ± 6.9

30.2 ± 8.3

0.13

Right lentiform nucleus

24.1 ± 7.5

28.8 ± 5.5

0.03

Left lentiform nucleus

24.6 ± 5.7

28.0 ± 6.1

0.04

Table 3. Regional cerebral blood volume values determined by perfusion computed tomography in
patients with Alzheimer disease and control subjects.
Brain region

Alzheimer disease

Control subjects

P-value

Right frontal cortex

36.2 ± 8.0

36.4 ± 5.8

0.93

Left frontal cortex

36.3 ± 9.5

37.5 ± 7.1

0.66

Right temporal cortex

40.7 ± 7.7

42.3 ± 6.4

0.49

Left temporal cortex

40.0 ± 9.5

42.6 ± 7.2

0.35

Right occipital cortex

42.1 ± 10.7

41.9 ± 8.5

0.95

Left occipital cortex

42.6 ± 8.4

39.5 ± 8.8

0.29

Right lentiform nucleus

35.2 ± 10.9

37.1 ± 4.2

0.49

Left lentiform nucleus

37.5 ± 7.9

36.5 ± 5.2

0.666

decreased regional CBF observed by PET and SPECT. The
specificity/sensitivity of 18F-fluorodeoxyglucose PET is
limited; however, 15O H2O PET or SPECT can be used
to show perfusion deficits (decreased regional CBF) in the
hippocampus and temporal and parietal regions (6,8,18–20).
Although volumetric studies and perfusion MRI, PET,
and SPECT methods are evolving rapidly, the application of
these technologies to the clinical investigation of dementia is

still limited due to availability and cost (16). PCT represents
an inexpensive, noninvasive, and widely available tool that
can be applied to measure brain perfusion quantitatively.
This technique is usually used for evaluating decreased
perfusion in patients with acute stroke. In addition, it can
be used to detect brain tumor perfusion and brain perfusion
with vessel stenosis or vasospasm after trauma. There are
few reports on the use of PCT in dementia (17,20,21).
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Table 4. Time-to-peak values determined by perfusion computed tomography in patients with
Alzheimer disease and control subjects.
Brain region

Alzheimer disease

Control subjects

P-value

Right frontal cortex

0.97 ± 0.17 s

0.82 ± 0.16 s

0.009

Left frontal cortex

0.92 ± 0.27s

0.77 ± 0.16 s

0.05

Right temporal cortex

1.00 ±0.13 s

0.85 ± 0.15 s

0.004

Left temporal cortex

0.98 ± 0.14 s

0.83 ± 0.12 s

0.002

Right occipital cortex

1.05 ± 0.17 s

0.88 ± 0.14 s

0.003

Left occipital cortex

1.07 ± 0.18 s

0.89. ± 0.14 s

0.002

Right lentiform nucleus

0.93 ± 0.18 s

0.78 ± 0.14 s

0.009

Left lentiform nucleus

0.91 ±0.17 s

0.78. ± 0.14s

0.02

Zimny et al. (19) performed PCT in 41 patients with AD,
vascular dementia, or mixed dementia. They showed that
rCBF and rCBV values in the grey and white matter of the
bilateral frontal and temporal lobes were lower in patients
with AD than in patients with vascular dementia; however,
the authors found no significant difference in rCBF, rCBV,
or rMTT between patients with AD and patients with
mixed dementia. However, the authors did not include
control subjects in that study. Streitparth et al. (18) found
that the occipital and temporal blood volume decreased
significantly with an increasing degree of dementia. They
showed regional hypoperfusion in the frontal, basal ganglia,
temporal, and occipital region in the group with AD when
compared with the group of cognitively normal subjects.
They suggested that PCT may be useful in differentiating
severity and types of dementia. Zimny et al. (19) suggest
that analysis of CBF and CBV parameters assessed in PCT
can be useful in evaluating cognitive impairment in patients
with dementia and may thus have a role in monitoring
disease progression or therapeutic response.
In the present study, we aimed to show usefulness of
PCT in evaluation of brain perfusion in AD. We included
15 cognitively normal control subjects and compared their
perfusion findings with those of the AD group. Our study
demonstrated cerebral cortical perfusion failure in AD by
using PCT. We observed decreased rCBF in the frontal and
temporal cortex and bilateral lentiform nucleus. It should
be noted that perfusion parameters are relative values that
depend on software programs and that they are lower than
physiological values in patient and control groups.
It is known that CBF is the most important parameter
for ischemia of PCT. It is measured in milliliters of blood
per 100 g brain tissue/min. CBF values obtained from
areas of the brain with high energy requirements such
as the cortical surface or basal ganglia were higher than
those from the white matter. In the AD group, diffuse
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vascular disturbances affected large brain regions as
compared with vascular dementia caused by focal vascular
pathology (20). This result may be related to decreased
rCBF values. CBF is controlled by changes in the vessel
diameter (autoregulation) and local calculated rCBF can
change depending on software program, injection speed,
and cardiac function. rCBV is defined as the percentage
of blood vessels in a specific volume of tissue. It is a
functional parameter and alters with vessel size changes in
the context of vascular autoregulation. In our study, there
was no significant difference in rCBV values between the
two groups. This finding may be explained with vessel
size changes. We also observed increasing rTTP values
in bilateral frontal, temporal, and occipital cortex, and
lentiform nucleus. It is known that mean transit time
(MTT) and TTP values indicate retarded perfusion, but
these values are not generally specific. It is also known
that rTTP values are affected by cardiac problems, but
our perfusion program did not contain MTT maps. A
metabolic decrease and hypoperfusion have been reported
to occur in the posterior parietal cortex, temporal cortex,
and limbic system in patients with AD. We also found
hypoperfusion of the temporal lobes in patients with AD,
as well as a decrease in regional CBF in the frontal lobes
and bilateral lentiform nucleus, when compared with
control subjects. Previous studies have shown that mild
AD is localized more in the cingulate gyrus and that a
more advanced disease is localized in the temporoparietal
and frontal cortices (2,14). Tang et al. (22) showed that
the CBV and CBF of the frontal and temporal lobe,
hippocampus, and basal ganglia in patients with senile
dementia were much lower, and the MTT and TTP of
these areas were higher than those values in the healthy
group at a low-dose perfusion program. We did not use
this program in a 4-slice scanner, but our dose values were
within safe limits.
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The patients in the present study had moderate to
advanced AD; hypoperfusion of the frontal, temporal, and
basal ganglia regions was observed. One limitation of the
present study is its limited coverage, which is a disadvantage
of perfusion CT. Perfusion evaluation at the hippocampal
level and parietal lobes was not possible in this technique in
our 4-slice CT scanner. Second, we could not evaluate the
relationship between cognitive impairment according to

the MMSE and according to perfusion parameters. Further
studies are needed to evaluate the role of PCT in monitoring
disease progression and therapy response in patients with AD.
In conclusion, PCT is readily available and cost effective
compared with other perfusion techniques for evaluation
of brain perfusion in AD patients. rCBF values can be
more useful in assessing hypoperfusion in the bilateral
frontal and temporal lobes and the lentiform nucleus.
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